Actualizado 22/02/2008 18:28
- Comunicado -

Bristol-Myers Squibb and Otsuka Receive Positive CHMP Opinion for ABILIFY(R) (aripiprazole) in Bipolar I Disorder (y 2)

9. American Psychiatric Association 2000. (DSM-IV-TR) Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Press, Inc. p320-323, 328-330, 333, 350-351.

10. Royal College of Psychiatrists. Bipolar Disorder (Manic Depression). http://www.rcpsych.ac.uk/mentalhealthinf... Date accessed 11 January 2007.

CONTACT: Carmel Hogan, Bristol-Myers Squibb Company, Mobile: +33-6-74-10-76-58, carmel.hogan@bms.com; Alison Ross, Otsuka Pharmaceutical Europe Ltd, Mobile: +44-(0)7768-337-128, aross@otsuka-europe.com

Contenido patrocinado